Article
Oncology
Sara Alonso-Alvarez, Martina Manni, Silvia Montoto, Clementine Sarkozy, Franck Morschhauser, Marielle J. Wondergem, Attilio Guarini, Laura Magnano, Miguel Alcoceba, Martine Chamuleau, Sara Galimberti, Maria Gomes da Silva, Harald Holte, Emanuele Zucca, Sandra Lockmer, Igor Aurer, Luigi Marcheselli, Yana Stepanishyna, Maria Dolores Caballero Barrigon, Gilles Salles, Massimo Federico
Summary: Patients with PREF FL have a significantly increased risk of histological transformation, poor prognosis, and lower survival rates compared to other FL patients.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Hematology
W. Richard Burack, Hongli Li, Diana Adlowitz, Janice M. Spence, Lisa M. Rimsza, Mazyar Shadman, Catherine M. Spier, Mark S. Kaminski, John P. Leonard, Michael L. Leblanc, Sonali M. Smith, Jonathan W. Friedberg
Summary: Subclonal TP53 mutations are common in follicular lymphoma and are distinct from AICDA-mediated genetic heterogeneity. Patients with no detectable subclonal mutation in TP53 benefit particularly from RIT.
Article
Hematology
Kostiantyn Dreval, Laura K. Hilton, Manuela Cruz, Haya Shaalan, Susana Ben-Neriah, Merrill Boyle, Brett Collinge, Krysta M. Coyle, Gerben Duns, Pedro Farinha, Bruno M. Grande, Barbara Meissner, Prasath Pararajalingam, Christopher K. Rushton, Graham W. Slack, Jasper Wong, Andrew J. Mungall, Marco A. Marra, Joseph M. Connors, Christian Steidl, David W. Scott, Ryan D. Morin
Summary: Follicular lymphoma (FL) accounts for approximately 20% of new lymphoma cases. In this study, two genetically distinct subgroups of FL, called DLBCL-like (dFL) and constrained FL (cFL), were identified and characterized based on whole-genome sequencing data. Using a machine learning approach, patients with FL could be stratified into cFL and dFL subgroups, and it was found that cFL status is associated with a reduced risk of lymphoma transformation.
Article
Oncology
Hideki Uryu, Yuko Mishima, Naoko Tsuyama, Masahiro Yokoyama, Noriko Nishimura, Takanori Fukuta, Yuko Shirouchi, Takashi Okabe, Norihito Inoue, Kengo Takeuchi, Yasuhito Terui
Summary: The study shows that rituximab maintenance therapy can improve the prognosis of patients with concurrent-DLBCL/FL, leading to better overall survival, progression-free survival, and reduced risk of relapse. Additionally, concurrent-DLBCL/FL demonstrates better survival outcomes after recurrence.
LEUKEMIA & LYMPHOMA
(2021)
Article
Hematology
Lucile Bussot, Simon Chevalier, Justine Cristante, Beatrice Grange, Bruno Tesson, Clemence Deteix-Santana, Frederique Orsini-Piocelle, Cecile Leyronnas, Sophie Dupire, Remy Gressin, Gilles Salles, Emmanuel Bachy, Anouk Emadali, Severine Valmary-Degano, Sarah Huet, Christine Lefebvre, Sylvain Carras
Summary: MYC-EC has no prognostic impact on FL in terms of disease progression and patient survival, while MYC-R FL may be associated with increased risk of transformation and poorer outcomes.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Letter
Oncology
Jie Zha, Liyuan Fan, Shuhua Yi, Haifeng Yu, Zhong Zheng, Wei Xu, Manman Deng, Zhijuan Lin, Zhifeng Li, Lingyan Ping, Xiaohua He, Feili Chen, Ying Xie, Biyun Chen, Huilai Zhang, Li Wang, Kaiyang Ding, Wenyu Li, Haiyan Yang, Weili Zhao, Lugui Qiu, Zhiming Li, Yuqin Song, Bing Xu
Summary: This study analyzed the clinical characteristics and outcomes of FL patients in China, revealing differences in features between Chinese and Western patients but similar overall prognosis. Adding rituximab to treatment led to the best outcomes, while histologic transformation was associated with poor survival.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Oncology
Javier Arzuaga-Mendez, Maria Lopez-Santillan, Juan Carlos Garcia-Ruiz, Elixabet Lopez-Lopez, Idoia Martin-Guerrero
Summary: MiRNAs show diagnostic potential in follicular lymphoma, with miR155-5p and miR-9-3p identified as potential diagnostic biomarkers. However, further research is needed to explore the prognostic and transformation prediction potential of MiRNAs in FL.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, Jose Antonio Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andres Jose Maria Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thieblemont
Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.
Article
Oncology
Ewa Paszkiewicz-Kozik, Malgorzata Debowska, Natalia Jakacka, Martyna Kotarska, Marcin Szymanski, Kamil Wisniewski, Agnieszka Konska, Malgorzata Jarzembowska, Joanna Drozd-Sokolowska, Joanna Romejko-Jarosinska, Anna Szumera-Cieckiewicz, Grzegorz Rymkiewicz, Bogna Ziarkiewicz-Wroblewska, Ewa Lech-Maranda, Jan Walewski, Iwona Hus
Summary: This study analyzed the management and prognosis of newly diagnosed patients with follicular lymphoma (FL) in real-world experience. The data showed that rituximab and chemotherapy is still an effective method of treatment for FL, resulting in a median progression-free survival of 8.28 years and overall survival exceeding 8 years in most patients. RCVP protocol followed by rituximab maintenance is a reasonable choice for the first-line therapy, especially in low/intermediate risk patients.
Article
Oncology
Yanan Li, Yan Zhang, Wei Wang, Chong Wei, Danqing Zhao, Wei Zhang
Summary: This study aims to evaluate prognostic predictors of follicular lymphoma among Chinese patients. The study found that LMR is a new independent predictor that has better predictive ability compared to FLIPI.
CANCER MANAGEMENT AND RESEARCH
(2022)
Article
Hematology
Takuro Yoshimura, Hiroaki Miyoshi, Joji Shimono, Kazutaka Nakashima, Mai Takeuchi, Eriko Yanagida, Kyohei Yamada, Yasumasa Shimasaki, Mayuko Moritsubo, Takuya Furuta, Kei Kohno, Koichi Ohshima
Summary: CD37 is a tetraspanin protein expressed in FL patients, and its expression is associated with tumor progression and prognosis. CD37-negative cases with high FLIPI have poor overall survival. CD37 may serve as a potential therapeutic target for FL.
ANNALS OF HEMATOLOGY
(2022)
Letter
Medicine, General & Internal
Leonid L. Yavorkovsky
Summary: The median survival of mantle-cell lymphoma is a puzzling issue. Despite the historically modest benefits of rituximab therapy, the introduction of rituximab has substantially improved the survival probability among patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Hematology
Emmanuel Bachy, Roch Houot, Pierre Feugier, Krimo Bouabdallah, Reda Bouabdallah, Emmanuelle Nicolas Virelizier, Marie Maerevoet, Christophe Fruchart, Sylvia Snauwaert, Steven Le Gouill, Jean-Pierre Marolleau, Lysiane Molina, Cecile Molucon-Chabrot, Catherine Thieblemont, Herve Tilly, Fontanet Bijou, Corinne Haioun, Eric Van den Neste, Bettina Fabiani, Michel Meignan, Guillaume Cartron, Gilles Salles, Olivier Casasnovas, Franck Morschhauser
Summary: The combination of Obinutuzumab and lenalidomide has shown promising clinical efficacy and a manageable safety profile in various types of lymphoma. This study reported the efficacy and safety results for previously untreated patients with advanced follicular lymphoma. The combination treatment resulted in a high complete response rate, overall response rate, and favorable progression-free survival and overall survival. The most common adverse event was neutropenia.
Article
Oncology
Cristina Correia, Matthew J. J. Maurer, Samantha J. J. McDonough, Paula A. A. Schneider, Paige E. E. Ross, Anne J. J. Novak, Andrew L. L. Feldman, James R. R. Cerhan, Susan L. L. Slager, Thomas E. E. Witzig, Bruce W. W. Eckloff, Hu Li, Grzegorz S. S. Nowakowski, Scott H. H. Kaufmann
Summary: The identification of follicular lymphoma (FL) patients with low disease burden but high risk for early progression is unclear. In a study on newly diagnosed FLs, BCL2 mutations with high variant allele frequency (VAF) were found to be associated with increased transformation risk and shorter event-free survival. However, other sequenced genes did not contribute significantly to the prognostic value of the panel. Nonsynonymous BCL2 mutations with VAF = 20% were consistently associated with decreased event-free survival and overall survival.
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
David A. Russler-Germain, Kilannin Krysiak, Cody Ramirez, Matthew Mosior, Marcus P. Watkins, Felicia Gomez, Zachary L. Skidmore, Lee Trani, Feng Gao, Susan Geyer, Amanda F. Cashen, Neha Mehta-Shah, Brad S. Kahl, Nancy L. Bartlett, Juan P. Alderuccio, Izidore S. Lossos, Sarah L. Ondrejka, Eric D. Hsi, Peter Martin, John P. Leonard, Malachi Griffith, Obi L. Griffith, Todd A. Fehniger
Summary: This study conducted a clinicogenomic analysis of follicular lymphoma (FL) patients and identified specific gene mutations associated with patient outcomes. They defined a mutations associated with progression (MAP) signature that can predict the progression risk of FL, providing insights for identifying high-risk subsets of patients.
Article
Oncology
Samantha J. Jones, Sumara Stroshein, Amy M. Williams, Dongmeng Liu, John J. Spinelli, Joseph M. Connors, Angela R. Brooks-Wilson
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2020)
Letter
Hematology
Keren Isaev, Daisuke Ennishi, Laura Hilton, Brian Skinnider, Karen L. Mungall, Andrew J. Mungall, Mehran Bakthiari, Rosemarie Tremblay-LeMay, Anjali Silva, Susana Ben-Neriah, Merrill Boyle, Diego Villa, Marco A. Marra, Christian Steidl, Randy D. Gascoyne, Ryan D. Morin, Kerry J. Savage, David W. Scott, Robert Kridel
Letter
Hematology
David D. W. Twa, Derrick G. Lee, King L. Tan, Graham W. Slack, Susana Ben-Neriah, Diego Villa, Joseph M. Connors, Laurie H. Sehn, Anja Mottok, Randy D. Gascoyne, David W. Scott, Christian Steidl, Kerry J. Savage
Article
Oncology
Martin Hutchings, John Radford, Stephen M. Ansell, Arpad Illes, Anna Sureda, Joseph M. Connors, Alice Sykorova, Hirohiko Shibayama, Jeremy S. Abramson, Neil S. Chua, Jonathan W. Friedberg, Jan Koren, Ann Steward LaCasce, Lysiane Molina, Gerald Engley, Keenan Fenton, Hina Jolin, Rachael Liu, Ashish Gautam, Andrea Gallamini
Summary: The study compared the efficacy and safety of different treatment regimens for Hodgkin lymphoma Stage IV patients, finding that A + AVD treatment improved PFS significantly for IV patients, with higher rates of adverse events such as peripheral neuropathy and neutropenia compared to the ABVD treatment group. In the high-risk patient subgroup, no increased incidence or severity of adverse events was observed.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Hematology
Gerben Duns, Elena Vigano, Daisuke Ennishi, Clementine Sarkozy, Stacy S. Hung, Elizabeth Chavez, Katsuyoshi Takata, Christopher Rushton, Aixiang Jiang, Susana Ben-Neriah, Bruce W. Woolcock, Graham W. Slack, Eric D. Hsi, Jeffrey W. Craig, Laura K. Hilton, Sohrab P. Shah, Pedro Farinha, Anja Mottok, Randy D. Gascoyne, Ryan D. Morin, Kerry J. Savage, David W. Scott, Christian Steidl
Summary: Our investigation revealed that non-mediastinal PMBL-like lymphomas are a unique subgroup within DLBCL, showing distinct clinical and genetic features compared to conventional PMBL and DLBCL. These findings have potential implications for the subtyping of aggressive B-cell lymphomas and the development of targeted therapies.
Article
Oncology
Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, David W. Scott, Qingyuan Zhang, Wojciech Jurczak, Muhit Ozcan, Xiaonan Hong, Jun Zhu, Jie Jin, David Belada, Juan Miguel Bergua, Francesco Piazza, Heidi Mocikova, Anna Lia Molinari, Dok Hyun Yoon, Federica Cavallo, Monica Tani, Kazuhito Yamamoto, Koji Izutsu, Koji Kato, Myron Czuczman, Sarah Hersey, Adrian Kilcoyne, Jacqueline Russo, Krista Hudak, Jingshan Zhang, Steve Wade, Thomas E. Witzig, Umberto Vitolo
Summary: The ROBUST study aimed to compare the efficacy of lenalidomide plus R-CHOP with placebo/R-CHOP in previously untreated ABC-type DLBCL. While the primary end point of progression-free survival (PFS) was not met in all patients, there were trends favoring R2-CHOP over placebo/R-CHOP in patients with higher-risk disease. The safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Hematology
Alden A. Moccia, Kimberly Schaff, Ciara Freeman, Paul J. Hoskins, Richard J. Klasa, Kerry J. Savage, Tamara N. Shenkier, Randy D. Gascoyne, Joseph M. Connors, Laurie H. Sehn
Summary: Treatment with R-CEOP in DLBCL patients with absolute contraindications to anthracyclines showed no significant difference in 10-year time to progression and disease-specific survival compared to the R-CHOP group, but had a lower 10-year overall survival. Therefore, R-CEOP represents a useful alternative for DLBCL patients who cannot use anthracyclines.
Article
Oncology
Elizabeth Punnoose, Franklin Peale, Edith Szafer-Glusman, Guiyuan Lei, Richard Bourgon, An D. Do, Eugene Kim, Liping Zhang, Pedro Farinha, Randy D. Gascoyne, F. Javier Munoz, Maurizio Martelli, Anja Mottok, Gilles A. Salles, Laurie H. Sehn, John F. Seymour, Marek Trneny, Mikkel Z. Oestergaard, Kirsten E. Mundt, Umberto Vitolo
Summary: The expression of BCL2 in patients with DLBCL is associated with a poorer progression-free survival. The study supports the use of an IHC scoring system to select BCL2-positive patients for future research.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2021)
Article
Oncology
Dean A. Regier, Brandon Chan, Sarah Costa, David W. Scott, Christian Steidl, Joseph M. Connors, Aly Karsan, Marco A. Marra, Robert Kridel, Ian Cromwell, Samantha Pollard
Summary: This study examined the cost-effectiveness of adding ibrutinib to the treatment of patients under the age of 60 with ABC-DLBCL. The analysis found that genetic testing to diagnose ABC-DLBCL and providing ibrutinib along with standard care treatment had a low to moderate probability of being cost-effective, depending on decision maker willingness to pay and the cost of the genetic test.
Article
Hematology
Kai Zhu, Andrew Jamroz, Steven Huang, Diego Villa, Ciara L. Freeman, David W. Scott, Graham Slack, Laurie H. Sehn, Joseph M. Connors, Cynthia L. Toze, Kerry J. Savage, Alina S. Gerrie
Summary: Hodgkin variant Richter transformation (HvRT) is a rare and challenging complication of chronic lymphocytic leukaemia (CLL) with limited information on prognostic factors and treatment approaches. In a population-based cohort from British Columbia, poor clinical outcomes were observed in the majority of HvRT patients, although those who received curative-intent therapy had similar survival rates to older patients with de novo Hodgkin lymphoma.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Letter
Oncology
Andrea C. Lo, Caroline L. Holloway, Kerry J. Savage, Laurie H. Sehn, Daniel F. Worsley, Joseph M. Connors, Tom Pickles
LEUKEMIA & LYMPHOMA
(2022)
Letter
Oncology
Manik Chahal, Anna Hayden, Kerry J. Savage, Diego Villa, David W. Scott, Alina S. Gerrie, Andrea Lo, Matthew Chan, Tom Pickles, Joseph M. Connors, Laurie Helen Sehn, Ciara L. Freeman
LEUKEMIA & LYMPHOMA
(2022)
Article
Hematology
Brett Collinge, Susana Ben-Neriah, Lauren Chong, Merrill Boyle, Aixiang Jiang, Tomoko Miyata-Takata, Pedro Farinha, Jeffrey W. Craig, Graham W. Slack, Daisuke Ennishi, Anja Mottok, Barbara Meissner, Elizabeth A. Chavez, Alina S. Gerrie, Diego Villa, Ciara Freeman, Kerry J. Savage, Laurie H. Sehn, Ryan D. Morin, Andrew J. Mungall, Randy D. Gascoyne, Marco A. Marra, Joseph M. Connors, Christian Steidl, David W. Scott
Summary: This study analyzed MYC and BCL2 structural variants in de novo diffuse large B-cell lymphoma tumors, finding that BCL2 copy number variations were associated with increased expression while MYC copy number variations were not. In the context of atypical double-hit, MYC and BCL2 CNVs did not confer a similar gene expression profile as HGBL-DH/TH-BCL2. These results support the exclusion of MYC and BCL2 CNVs from HGBL-DH/TH and highlight the ability of a molecular-based classification system to identify tumors with shared biology that FISH and IHC fail to fully capture.
